Dr. Reddy’s preparing to file BLA/MAA dossiers for rituximab biosimilar

Jan 20, 2023

Dr. Reddy’s announced that it has successfully completed the full set of clinical studies of DRL_RI (proposed rituximab biosimilar) for filing in the US, EU and other regions against Roche/Biogen’s Rituxan®. DRL_RI will be commercialised by Fresenius Kabi in the US, and by Dr. Reddy’s directly in other jurisdictions.

Print Page Mail Article